论文部分内容阅读
最近妇女健康启动研究(WHI)和百万妇女研究(MWS)引起了对绝经后激素治疗的重新审视和评价。研究认为雌孕激素联合治疗(EPT)使乳腺癌的风险增加,而单用雌激素治疗至少在7年内没有发现乳腺癌风险的增加。所以,在做出开始或继续使用激素治疗时应充分考虑不同方案对乳腺的影响。以往的研究显示组织选择性雌激素活性调节剂利维爱较传统的激素治疗对乳腺刺激小。目前有一项正在进行的研究以评估是否利维爱可用于乳腺癌术后患者。
The recent Women’s Health Initiative Study (WHI) and the One Million Women Study (MWS) have led to a re-examination and evaluation of postmenopausal hormone therapy. Studies suggest that combined estrogen and progestogen therapy (EPT) increases the risk of breast cancer, whereas estrogen alone does not find an increased risk of breast cancer for at least seven years. Therefore, in making the start or continue to use hormone therapy should take full account of the impact of different programs on the breast. Previous studies have shown that tissue-selective estrogen activity modulator Levi than traditional hormone therapy on breast stimulation is small. There is an ongoing study to assess whether Levi can be used in patients with postoperative breast cancer.